IRS1 binds the NPM-ALK fusion protein through tyrosine residue 167. Mutation of this residue abrogates IRS1 binding, but the NPM-ALK Y167 mutant is still able to support the transforming activity of t
Kinase gene fusions are critical oncogenic drivers and key targets in precision oncology. Here, we report a previously undescribed out-of-frame CBX3::ALK fusion identified in metastatic melanoma. Rema